Royal DSM N.V.’s API business, DSM Pharma Chemicals, has entered into a commercialization agreement with Indoco Remedies Ltd. of Mumbai, India, for eight APIs. Indoco will manufacture the APIs that will be used for the production of pharmaceutical finished dosages, which DSM will market and sell. This alliance will leverage Indoco’s product development and cGMP manufacturing capabilities and DSM’s market access.

Alexander Wessels, president and chief executive officer of DSM Pharmaceutical Products (DPP), said, “This is a step in our announced strategy to accelerate growth via partnerships and expansion in Asia to build a product portfolio alongside our custom manufacturing operations, supplying access to high demand treatments. It allows DPP to build a competence base in India.”

Mr. Suresh G. Kare, chairman and managing director of Indoco Remedies, said, “Today in the era of alliances and partnerships, organizations are coming together to penetrate and capture a larger share of the potential opportunities in the market place. Indoco is active in forging such alliances and this one with DSM is a step in that direction. This alliance offers a great opportunity to expand our global presence with a well established partner like DSM.”